TOLEDO, Spain, June 16, 2016 /PRNewswire/ --

Medical distributor Presurgy S.L. tapped to oversee distribution of UroLift System, which is highlighted at The Spanish National Congress Of Urology (AEU) as an effective treatment for men with enlarged prostate. 

The UroLift® System treatment for enlarged prostate is to be showcased tomorrow (June 17) at the Spanish National Congress of Urology meeting in Toledo, Spain, with a poster presentation outlining local experience. This comes following the presentation of the four-year durability results of the multi-national L.I.F.T. randomised study and the two-year results of the multi-national BPH6 randomised study in March at the European Association of Urology Congress in Munich.  These promising results are presented as NeoTract announces the appointment of a urology specialist distributor for UroLift in Spain: Presurgy S.L.

The news comes as the EAU Guidelines for male lower urinary tract symptoms (LUTS) upgraded the rating for UroLift data to the highest possible classification, Level 1A, and as NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announces key gains in European government healthcare system reimbursement in multiple markets.

In the UK, UroLift is now being offered by 17 publicly-funded NHS hospitals following positive NICE (National Institute for Health and Care Excellence) guidance based on a review of the economic and clinical benefits and revised tariff coding in September of last year. In Denmark, UroLift is being offered in a growing number of Government-funded hospitals following a trial at Herlev Hospital in Copenhagen.

NeoTract's EMEA Vice President and General Manager, Justin Hall, says: "Following the recent positive evaluation by NICE in the UK, we want to deliver a similar model as we've used in the UK to Spain. Our aim is to showcase how the national healthcare system - from primary care to hospitals - in Spain can make significant cost and efficiency savings using UroLift. By partnering with a urology specialist distributor, Presurgy, to deliver that on our behalf, we believe we will enjoy wider take up in Spain."

"Daily, we see evidence of increasing demand across Europe from patients and their partners for the UroLift System, a less invasive, true day case procedure that can be carried out under local anesthesia, avoids the otherwise common negative impact on sexual function, and rapidly improves quality of life for couples whose lives are severely impacted by BPH. UroLift's safety profile, clinical efficacy and substantial care pathway cost savings were recognized last year by the UK body and are now more than persuasive as we operate under ever more complex and demanding government healthcare-funding arrangements across Europe. Today, payors rightly demand the most rigorous economic and clinical data to support the adoption of new technology. Our new Level 1A endorsement from the EAU, based on our robust mid range clinical data, will further progress our mission to make this life-changing treatment available to all suitable men with BPH across Europe."

SOURCE NeoTract, Inc.